Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Larry D Anderson

Showing results (71-80 of 114) with videos related to

Pageof 12
Sort By:
Journal of Hematology & Oncology|June 6, 2024
Impact of extramedullary multiple myeloma on outcomes with idecabtagene vicleucelSaurabh Zanwar, Surbhi Sidana, Leyla Shune, et al.
American Journal of Hematology|April 16, 2024
Health-related quality of life in transplant-eligible patients with newly diagnosed multiple myeloma treated with daratumumab, lenalidomide, bortezomib, and dexamethasone: Patient-reported outcomes from GRIFFINRebecca Silbermann, Jacob Laubach, Jonathan L Kaufman, et al.
American Journal of Hematology|November 12, 2025
The Real-World Safety and Efficacy of Bispecific T-Cell Engager Therapy in Systemic AL AmyloidosisMatthew J Rees, Jack Khouri, Ariel F Grajales-Cruz, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|January 18, 2023
Systemic Light Chain Amyloidosis, Version 2.2023, NCCN Clinical Practice Guidelines in OncologyShaji K Kumar, Natalie S Callander, Kehinde Adekola, et al.
Blood|April 8, 2025
Standard-of-Care Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma: A CIBMTR AnalysisSurbhi Sidana, Nausheen Ahmed, Othman Salim Akhtar, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|January 6, 2022
NCCN Guidelines® Insights: Multiple Myeloma, Version 3.2022Natalie S Callander, Muhamed Baljevic, Kehinde Adekola, et al.
Blood Cancer Journal|July 8, 2024
Daratumumab in transplant-eligible patients with newly diagnosed multiple myeloma: final analysis of clinically relevant subgroups in GRIFFINAjai Chari, Jonathan L Kaufman, Jacob Laubach, et al.
Future Oncology (London, England)|October 25, 2024
A plain language summary of the final analysis of the GRIFFIN study of daratumumab plus lenalidomide, bortezomib, and dexamethasone for people with newly diagnosed multiple myelomaPeter M Voorhees, Douglas W Sborov, Jacob Laubach, et al.
Blood Cancer Journal|March 21, 2026
Efficacy of stem cell boost (SCB) for chimeric antigen receptor-T cell therapy (CAR-T)-related hematologic toxicity in patients with relapsed/refractory multiple myeloma (RRMM)-real world experience from the US multiple myeloma immunotherapy consortiumCindy Varga, Myra Robinson, James A Davis, et al.
The Lancet. Oncology|May 31, 2024
Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy CommitteeYi Lin, Lugui Qiu, Saad Usmani, et al.
Pageof 12

Showing results (71-80 of 114) with videos related to

Sort By:
Pageof 12
Journal of Hematology & Oncology|June 6, 2024
Impact of extramedullary multiple myeloma on outcomes with idecabtagene vicleucelSaurabh Zanwar, Surbhi Sidana, Leyla Shune, et al.
American Journal of Hematology|April 16, 2024
Health-related quality of life in transplant-eligible patients with newly diagnosed multiple myeloma treated with daratumumab, lenalidomide, bortezomib, and dexamethasone: Patient-reported outcomes from GRIFFINRebecca Silbermann, Jacob Laubach, Jonathan L Kaufman, et al.
American Journal of Hematology|November 12, 2025
The Real-World Safety and Efficacy of Bispecific T-Cell Engager Therapy in Systemic AL AmyloidosisMatthew J Rees, Jack Khouri, Ariel F Grajales-Cruz, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|January 18, 2023
Systemic Light Chain Amyloidosis, Version 2.2023, NCCN Clinical Practice Guidelines in OncologyShaji K Kumar, Natalie S Callander, Kehinde Adekola, et al.
Blood|April 8, 2025
Standard-of-Care Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma: A CIBMTR AnalysisSurbhi Sidana, Nausheen Ahmed, Othman Salim Akhtar, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|January 6, 2022
NCCN Guidelines® Insights: Multiple Myeloma, Version 3.2022Natalie S Callander, Muhamed Baljevic, Kehinde Adekola, et al.
Blood Cancer Journal|July 8, 2024
Daratumumab in transplant-eligible patients with newly diagnosed multiple myeloma: final analysis of clinically relevant subgroups in GRIFFINAjai Chari, Jonathan L Kaufman, Jacob Laubach, et al.
Future Oncology (London, England)|October 25, 2024
A plain language summary of the final analysis of the GRIFFIN study of daratumumab plus lenalidomide, bortezomib, and dexamethasone for people with newly diagnosed multiple myelomaPeter M Voorhees, Douglas W Sborov, Jacob Laubach, et al.
Blood Cancer Journal|March 21, 2026
Efficacy of stem cell boost (SCB) for chimeric antigen receptor-T cell therapy (CAR-T)-related hematologic toxicity in patients with relapsed/refractory multiple myeloma (RRMM)-real world experience from the US multiple myeloma immunotherapy consortiumCindy Varga, Myra Robinson, James A Davis, et al.
The Lancet. Oncology|May 31, 2024
Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy CommitteeYi Lin, Lugui Qiu, Saad Usmani, et al.
Pageof 12